Medical imaging suite with a patient undergoing a brain scan while multiple monitors display diagnostic images
16 Nov 2026

How AI, Evolving Regulations, Cybersecurity, and Global Market Access Are Reshaping the Path from Medical Technology Innovation to Commercialization

The MedTech Conference 2026 in Boston brought together leaders, innovators, regulators, investors, and policymakers from across the global medical technology ecosystem. Across discussions on artificial intelligence, regulatory policy, cybersecurity, global market access, and commercialization, a consistent message emerged: innovation in medtech continues to accelerate, and the regulatory and quality ecosystem supporting that innovation must evolve just as quickly.

AI and digital health have moved rapidly from emerging technologies to strategic priorities throughout the medtech industry. Connected patient monitors, wearable and remote monitoring technologies, AI-enabled imaging and diagnostic platforms, clinical decision-support software, and other software-driven medical devices are changing not only how healthcare is delivered, but also how medical technologies are developed and regulated.

As the capabilities of these products expand, manufacturers must look beyond functionality alone and address safety, performance, software validation, cybersecurity, data integrity, interoperability, and lifecycle management from the earliest stages of development.

The challenge becomes even more significant as devices receive software updates, interact with other connected systems, or incorporate algorithms that may evolve over time. The opportunity for innovation is enormous, but ultimately its success will depend on whether manufacturers can demonstrate that these technologies are not only innovative, but also safe, secure, reliable, and worthy of patient and clinician trust.

Regulatory strategy is also becoming increasingly intertwined with product and business strategy. In the United States, ongoing discussions surrounding Food and Drug Administration (FDA) priorities and Medical Device User Fee Amendments (MDUFA) VI highlight the continued focus on regulatory efficiency, predictability, and the ability of the regulatory system to keep pace with increasingly sophisticated medical technologies.

For manufacturers, the implication is significant: regulatory considerations cannot simply begin when a product is ready for submission. They must be incorporated much earlier into development, testing and commercialization strategies.

Closely connected to this is the growing focus on regulatory science and confidence in conformity assessment. Programs such as FDA's Accreditation Scheme for Conformity Assessment (ASCA), demonstrate how greater confidence in accredited testing can help create a more consistent and efficient regulatory pathway. As medical technologies grow more complex, earlier alignment around standards, testing strategies, and evidence requirements can help manufacturers identify potential issues sooner, strengthen submission readiness, and reduce unnecessary uncertainty later in the development process.

Cybersecurity, quality, and lifecycle management are becoming inseparable from innovation. Today's medical technologies may evolve long after their initial introduction to the market through software updates, connectivity, changing cybersecurity threats, and other modifications.

At the same time, manufacturers are navigating areas such as quality management, biocompatibility, human factors, and emerging approaches to clinical and real-world evidence. Collectively, these considerations reinforce a fundamental shift: successful market access increasingly depends on decisions made throughout the product lifecycle, rather than activities undertaken immediately before regulatory submission.

The industry is also navigating the global nature of both opportunity and regulatory complexity. Medical technology companies increasingly develop products with multiple markets in mind, yet regulatory frameworks, standards, evidence expectations, and market-access requirements can vary significantly across regions. Greater regulatory convergence and harmonization offer an opportunity to make global pathways more efficient, but manufacturers must still understand and plan for important regional differences. Developing a global regulatory and compliance strategy early can help organizations anticipate those differences rather than addressing them market by market later in the commercialization process.

Ultimately, one of the most important themes emerging from Boston is that the next phase of medtech will not be defined by innovation alone, but by the industry's ability to translate innovation into safe, trusted, and globally accessible products. Doing so will require continued collaboration among manufacturers, regulators, clinicians, standards organizations, testing and certification partners, and patients.

For organizations such as Intertek, it also creates an opportunity to engage earlier in the innovation lifecycle, helping manufacturers anticipate technical and regulatory requirements, build stronger evidence strategies, reduce uncertainty and ultimately bring meaningful medical technologies to patients more efficiently.

Headshot of Clarissa Benfield
Clarissa Benfield

Global Director and Business Leader, Medical, Laboratory, and Life Safety & Security

With more than 15 years of experience supporting the Assurance, Testing, Inspection, and Certification industry, Clarissa is dedicated to Intertek’s mission of bringing quality, safety, and sustainability to life. As a leader in the medical and laboratory space, she is passionate about working with manufacturers bringing innovative technologies and life-altering products to market.

You may be interested in...